Related Experiment Video
Updated: Jan 30, 2026

Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection
Published on: August 20, 2007
Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics
Simon Braumann1, Stephan Baldus1, Roman Pfister1
1Department of Cardiology, Heart Center, University of Cologne, Cologne Cardiovascular Research Center, Cologne, Germany.
Abstract:
Novel cancer therapeutics contribute to a steadily declining cancer mortality. However, several of these new therapies target pathways also involved in the cardiovascular system thus causing cardiotoxic side effects such as chemotherapy-induced heart failure (CIHF). This might limit the applicability of these effective treatments in a relevant number of patients. Furthermore, given the improving cancer survival rates, chemotherapy-induced cardiotoxic complications receive increasing attention given their potential impact on long-term morbidity and mortality. The understanding of molecular mechanisms that underlie CIHF is crucial for future improvement of pharmacodynamics of these therapeutics but also for developing specific interventions to prevent CIHF. Here, we discuss molecular mechanisms underlying CIHF of novel cancer therapeutics including a short synopsis on clinical management of patients suffering from CIHF.
Insights
Novel cancer therapies can cause heart failure, known as chemotherapy-induced heart failure (CIHF). Understanding CIHF's molecular basis is key to improving cancer treatments and preventing heart damage.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Novel cancer therapeutics are improving survival rates but can cause cardiotoxic side effects.
- Chemotherapy-induced heart failure (CIHF) is a significant concern, impacting long-term patient morbidity and mortality.
- Understanding the molecular mechanisms of CIHF is crucial for managing these side effects.
Purpose of the Study:
- To discuss the molecular mechanisms underlying chemotherapy-induced heart failure (CIHF) from novel cancer therapeutics.
- To provide a synopsis on the clinical management of patients experiencing CIHF.
- To highlight the importance of understanding CIHF for improving cancer treatment efficacy and patient outcomes.
Main Methods:
- Review of current literature on molecular mechanisms of CIHF.
- Synopsis of clinical management strategies for CIHF.
- Discussion of the interplay between cancer therapy pathways and cardiovascular system.
Main Results:
- Novel cancer drugs target pathways that can lead to cardiotoxicity, including heart failure.
- CIHF poses a significant risk to patients undergoing cancer treatment, affecting long-term health.
- Detailed understanding of molecular pathways is essential for developing targeted interventions.
Conclusions:
- Further research into the molecular underpinnings of CIHF is necessary.
- Developing specific interventions to prevent or manage CIHF is critical for optimizing cancer therapy.
- Integrated approaches combining oncology and cardiology are needed for comprehensive patient care.
More Related Videos
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanisms of Retrovirus-induced Cancers
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Therapeutic Index
Molecular Models
Molecular Orbital Theory II